U.S. Markets closed
  • S&P 500

    3,841.47
    -11.60 (-0.30%)
     
  • Dow 30

    30,996.98
    -179.03 (-0.57%)
     
  • Nasdaq

    13,543.06
    +12.15 (+0.09%)
     
  • Russell 2000

    2,168.76
    +27.34 (+1.28%)
     
  • Crude Oil

    51.98
    -1.15 (-2.16%)
     
  • Gold

    1,855.50
    -10.40 (-0.56%)
     
  • Silver

    25.57
    -0.29 (-1.12%)
     
  • EUR/USD

    1.2174
    +0.0001 (+0.0122%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • Vix

    21.91
    +0.59 (+2.77%)
     
  • GBP/USD

    1.3685
    -0.0046 (-0.3339%)
     
  • USD/JPY

    103.7500
    +0.2450 (+0.2367%)
     
  • BTC-USD

    32,478.64
    +684.32 (+2.15%)
     
  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

Earnings Outlook for CytoSorbents

Benzinga Insights
·2 min read

CytoSorbents (NASDAQ: CTSO) announces its next round of earnings this Wednesday, November 04. Here is Benzinga's everything-that-matters guide for this Wednesday's Q3 earnings announcement.

Net Income, Earnings, And Earnings Per Share

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

CytoSorbents's per-share loss will be near $0.09 on sales of $9.51 million, according to Wall Street analysts. CytoSorbents EPS in the same period a year ago totaled $0.21. Revenue was $6.09 million.

Why Analyst Estimates And Earnings Surprises Are Important

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.

View more earnings on CTSO

If the company were to report earnings in line when it publishes results Wednesday, quarterly profit would be up 57.14%. Sales would be up 56.03% from the year-ago period. Here is how the CytoSorbents's reported EPS has stacked up against analyst estimates in the past:

Quarter

Q2 2020

Q1 2020

Q4 2020

Q3 2019

EPS Estimate

-0.08

-0.13

-0.17

-0.22

EPS Actual

-0.08

-0.10

-0.12

-0.21

Revenue Estimate

9.66 M

7.00 M

6.80 M

6.66 M

Revenue Actual

9.79 M

8.71 M

7.43 M

6.09 M

Stock Performance

Shares of CytoSorbents were trading at $8.04 as of November 02. Over the last 52-week period, shares are up 71.61%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. CytoSorbents is scheduled to hold the call at 16:45:00 ET and can be accessed here.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.